

LF-W



Practitioner's Docket No. 7492-104

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: BUNCE, Christopher Martin

Application No.: 10/581,376

Group No.: N/A

Int'l Filed: November 24, 2004

Examiner: N/A

For: BIOLOGICAL CELL CULTURE, CELL CULTURE MEDIA AND THERAPEUTIC USE OF BIOLOGICAL CELLS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF FILING OR
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. § 1.97(b))

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or

CERTIFICATION UNDER 37 C.F.R. ' ' 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is *mandatory*;
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. § 1.8(a)

with sufficient postage as first class mail.

Signature

Date: July 6, 2006


Linda J. Werk

(type or print name of person certifying)

* Only the date of filing (' 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under ' 1.8 continues to be taken into account in determining timeliness. See ' 1.703(f). Consider "Express Mail Post Office to Addressee" (' 1.10) or facsimile transmission (' 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. § 1.97(b).

Date: 6 July 2006

A handwritten signature in black ink, appearing to read 'R. Berliner', is written over a horizontal line.

Robert Berliner
Registration No. 20,121
Berliner & Associates
555 West Fifth Street, 31st Floor
Los Angeles, CA 90013
213-533-4171
Customer No. 000062836



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/581,376
Filing Date	11/24/2004
First Named Inventor	Christopher Martin Bunce
Art Unit	N/A
Examiner Name	N/A
Attorney Docket Number	7492-104

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		LUONG QUANG T ET AL., "Expression of Nm23-H1 in AML correlates with white cell count at diagnosis and in vitro acts as a survival factor for primary AMLs cells; evidence of a novel autocrine survival factor in AML," XP-001193730, Vol. 102 (No. 11), (November 16, 2003).	
		OKABE-KADO JUNKO ET AL., "Physiological and pathological relevance of extracellular NM23/NDP kinases," Journal of Bioenergetics and Biomembranes, XP008031558, Vol. 35 (No. 1), p. 89-93, (February 6, 2003).	
		OKABE-KADO JUNKO ET AL., "Inhibitory action of nm23 proteins on induction of erythroid differentiation of human leukemia cells," Biochimica Et Biophysica Acta, XP008031891, Vol. 126 (No. 2-3), p. 101-106,	
		OKABE-KADO J ET AL., "Identity of a differentiation inhibiting factor for mouse myeloid leukemia cells with NM23/nucleoside diphosphate kinase," XP008031856, Biochemical and Biophysical Research Communications, Vol. 182 (No. 3), p. 987-994,	
		LOMBARDI DANIELA ET AL., "nm23: Unraveling its biological function in cell differentiation," Journal of Cellular Physiology, XP008031851, Vol. 182 (No. 2), p. 144-149, (February 6, 2000).	
		NEGRONI A ET AL., "Neuroblastoma specific effects of DR-nm23 and its mutant forms on differentiation and apoptosis," Cell Death and Differentiation, XP008031853, Vol. 7 (No. 9), p. 843-850, (September 6, 2000).	
		MIYAZAKI H ET AL., "Overexpression of nm23-H2/NDP kinase B in a human oral squamous cell carcinoma cell line results in reduced metastasis, differentiated phenotype in the metastatic site, and growth factor-independent proliferative activity in culture," Clinical Cancer Research: An official Journal of the American Association for Cancer Research,	
		WILLEMS ROEL ET AL, "Decrease in nucleoside diphosphate kinase (NDPK/nm 23) expression during hematopoietic maturation," Journal of Biological Chemistry, XP002285299, Vol. 273 (No. 22), p. 13663-1366, (May 29, 1998).	
		VENTURELLI D ET AL., "Overexpression of DR-NM23, a protein encoded by a member of the NM23 Gene Family, inhibits Granulocyte Differentiation and Induces Apoptosis in 32DC13 Myeloid Cells," Proceedings of the National Academy of Sciences of USA, National Academy of Science, XP002942044, p. 7435-7439, (August 6, 1995).	
		GERVASI FABIO ET AL., "Nm23 Influences proliferation and differentiation of PC12 cells," Cell Growth and Differentiation, XP008031890, Vol. 7 (No. 12), p. 1689-1695,	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.